HagopM.KantarjianMDFASCO

PubMed

• Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
  Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
  Haematologica. 2024-12-12
• Acute myeloid leukemia management and research in 2025.
  Hagop M Kantarjian, Courtney D DiNardo, Tapan M Kadia, Naval G Daver, Jessica K Altman
  CA. 2024-12-10
• Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy.
  Wei Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M Kadia, Sa A Wang
  Blood Advances. 2024-12-04

Journal Articles

• Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor Therapy  
  Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Srdan Verstovsek, Blood
• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
• Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia  
  Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Hagop Kantarjian, MD, The New England Journal of Medicine
• Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML  
  Alexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood
• Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
  Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
• Improving Outcomes for Patients with Acute Myeloid Leukemia in First Relapse: A Single Center Experience  
  Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi F, Am J Hematol, 1/1/2015
• Post Hoc Analysis of the Relationship Between Baseline White Blood Cel Count and Survival Outcome in a Randomized Phase III Trial of Decitabine in Older Patients with ...  
  Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones M, Berrak E, Kantarjian H, Journal of Blood Medicine, 1/1/2015
• Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid ...  
  Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K..., Clin Lymphoma Myeloma Leuk, 1/1/2015
• Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center  
  Walter RB, Othus M, Burnett AK, Lowenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH, Leukemia, 1/1/2015
• The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes  
  Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H, Leuk Lymphoma, 1/1/2015
• A Phase I/II Study of the Janus Kinase (JAK) 1 and 2 Inhibitor Ruxolitinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia  
  Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S, Clin Lymphoma Myeloma Leuk, 1/1/2015
• Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis  
  Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, B..., Br J Haematol, 1/1/2015
• Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies  
  Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA, Clin Cancer Res, 1/1/2015
• Myelopathy Following Intrathecal Chemotherapy in Adults: A Single Institution Experience  
  Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K, J Neurooncol, 1/1/2015
• Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome  
  Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J, Am J Hematol, 1/1/2015
• Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute l...  
  Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S, Haematologica, 1/1/2015
• Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia  
  Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z, Br J Haematol, 1/1/2015
• High FISH percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome  
  Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S, Am J Hematol, 1/1/2015
• Monoclonal antibodies in acute lymphoblastic leukemia  
  Jabbour E, O'Brien S, Ravandi F, Kantarjian H, Blood, 1/1/2015
• Join now to see all

Books/Book Chapters

• Harrison's Principles of Internal Medicine 
  Chapter: Chronic Myeloid Leukemia 
  Page 687 - 695Kantarjian H, Cortes JEditors: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J.McGraw Hill, Chicago, IL2015
• The Molecular Basis of Cancer 
  Chapter: Biology of Adult Myelocytic Leukemia and Myelodysplasia 
  Page 421 - 432Post S, Kantarjian H, Quintas-Cardama AEditors: Mendelsohn J, Gray J, Howley P, Israel M, Thompson C.Elsevier Saunders, Philadelphia, PAEdition 4th,2014
• Cancer Consult Expertise for Clinical Practice 
  Chapter: Management of B-cell acute lymphoblastic leukemia 
  Page 22 - 28Ghanem H, Kantarjian H, Jain N, Jabbour EEditors: Syed A. Abutalib, Maurie Markman.John Wiley and Sons, Inc., Hoboken, NJEdition 1st,2014
• Hematology Basic Principles and Practice 
  Chapter: Clinical Manifestations and Treatment of Acute Myeloid Leukemia 
  Page 863 - 881Faderl S, Kantarjian HEditors: R Hoffman, E Benz, L Silberstein, H Heslop, J Weitz, J Anastasi.Elsevier Saunders, Philadelphia, PAEdition 6th,2012
• Goldman's Cecil Medicine 
  Chapter: The Chronic Leukemias 
  Page 1209 - 1217Kantarjiah H, O'Brien SEditors: Goldman L, Schaffer A.Elsevier Saunders, Philadelphia, PA2012
• Hematologic Malignancies in Children, Adolescents and Young Adults 
  Chapter: Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia in the Modern Era 
  Nachman, J, Kantarjian, HMEditors: Cairo MS, Perkins, SL.World Scientific Publishing, Singapore2012
• Advances in Malignant Hematology 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 228 - 244O'Brien S, Faderl S, Thomas D, Kantarjian HWiley-Blackwell, West Sussex, UK2011
• The MD Anderson Manual of Medical Oncology 
  Chapter: Chronic Myeloid Leukemia 
  Jabbour E. Fullmer A, Faderl S, Parikh S, Koller S, Kantarjian HEditors: Kantarjian H, Wolff R, Koller C.McGraw-Hill, ChinaEdition 2nd,2011
• Hematology / Oncology Clinics of North America: Chronic Myelogenous Leukemia 
  Chapter: Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment 
  Page 981 - 995Jabbour E, Parikh S, Kantarjian H, Cortes JEditors: DJ De Angelo, GP Canellos, N Berliner.W.B. Saunders Company, Philadelphia, PA2011
• Management of Hematologic Malignancies 
  Chapter: Chronoic Myeloid Leukemia 
  Page 68 - 80Jabbour E, Kantarjian H, Cortes JEditors: O'Brien S, Vose J, Kantarjian H.Cambridge University Press, New York, NYEdition 1st,2011
• Cancer - Principles & Practice of Oncology 
  Chapter: Myelodysplastic Syndromes 
  Page 1988 - 1996Kantarjian HEditors: DeVita V, Lawrence T, Rosenbert S.Lippincott Williams & Wilkins, Philadelphia, PAEdition 9th,2011
• Management of Hematologic Malignancies 
  Chapter: Myelodysplastic Syndromes (MDS) 
  Page 103 - 115Faderl S, Garcia-Manero G, Kantarjian HEditors: O'Brien S, Vose J, Kantarjian H.Cambridge University Press, New York, NYEdition 1st,2011
• Advances in Malignant Hematology 
  Chapter: Standard Management of Patients with Chronic Myeloid Leukemia 
  Page 71 - 86Jabbour E, Cortes J, Kantarjian HEditors: Saba H, Mufti G.Wiley-Blackwell, West Sussex UKEdition 1st,2011
• Cancer Medicine 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 1591 - 1603Faderl S, Pui C, O'Brien S, Kantarjian HEditors: Hong W, Bast R, Hait W, Kufe D, Pollock R, Weichselbaum R, Holland J, Frei E.People's Medical Publishing House-USA, Shelton, CTEdition 8th,2010
• Cancer Medicine 
  Chapter: Chronic Myeloid Leukemia 
  Page 1582 - 1590Cortes J, Silver R, Kantarjian HEditors: Hong W, Bast R, Hait W, Kufe D, Pollack R, Weichselbaum R, Holland J, Frei E.People's Medical Publishing House-USA, Shelton, CTEdition 8th,2010
• Cancer Management: A Multidisciplinary Approach 
  Chapter: Chronic myeloid leukemia 
  Page 807 - 822Cortes J, Silver RT, Kantarjian HEditors: Pazdur R, Wagman L, Camphausen K, Hoskins W.The Oncology Group of CMPMedia, Norwalk, CTEdition 12th,2009
• Antifungal strategies and complications in high-risk patients 
  Chapter: Prophylactic antifungal therapy in neutropenic onco-hematology patients 
  Page 18 - 36Mattiuzzi G, Kantarjian HRemedica, London, England2009
• Abeloff's Clinical Oncology 
  Chapter: Chronic myeloid leukemia 
  Page 2279 - 2291Kantarjian H, Cortes JEditors: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG.Churchill Livingstone, an imprint of Elsevier Inc, Philadelphia, PA2008
• Targeted Cancer Therapy 
  Chapter: Targeted therapy in myelodysplastic syndrome 
  Page 237 - 260Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Cortes JEditors: Kurzrock R, Markman M.Humana Press, a part of Springer Science+Business Media, LLC, Totowa, NJ2008
• Chronic Myeloid Leukemia 
  Chapter: Dasatinib: A dual ABL and SRC inhibitor 
  Page 59 - 68Quintas-Cardama A, Kantarjian H, and Cortes JEditors: Cortes J and Deininger M.Informa Healthcare USA, Inc, New York, NY2007
• Nilotinib (AMN 107) for the treatment of chronic myelogenous Leukemia 
  Page 69 - 77Jabbour E, Giles F, Cortes J, O'Brien S, and Kantarjian HEditors: Cortes J and Deininger M.Informa Healthcare USA, Inc, New York, NY2007
• Cecil Medicine 
  Chapter: The Chronic Leukemias 
  Page 1397 - 1408Kantarjian H and O'Brien SEditors: Goldman L, Ausiello E.Saunders Elsevier, Philadelphia, PA2007
• MD Anderson Manual of Medical Oncology 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 3 - 17Jabbour E, Borthakur G, Bueso-Ramos, C, Kantarjian H, Faderl SMcGraw Hill Professional, New York, NYEdition 1st,2006
• Cancer management: A multidisciplinary approach - medical, surgical & radiation oncology 
  Chapter: Chronic myelogenous leukemia 
  Page 797 - 810Cortes, J, Silver R, Kantarjian HCMP Healthcare Media2005
• Cancer management: A multidisciplinary approach - medical, surgical & radiation oncology 
  Chapter: Myelodysplastic syndromes 
  Page 825 - 842Cortes, J, List A, Kantarjian H2005
• Join now to see all

Abstracts/Posters

• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients wit...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Medical Crossfire¬: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia _ How the Experts Think and Treat 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a l... 
  2019 ASCO Annual Meeting - 6/1/2019
• New approaches in acute lymphoblastic leukemia therapy 
  Cancun, Mexico - 1/28/2012
• Front line therapy for CML 
  Beirut, Lebanon - 1/21/2012
• Treatment of high risk MDS 
  Beirut, Lebanon - 1/20/2012
• Elderly AML: A continuous challenge 
  Beirut, Lebanon - 1/20/2012
• What is New in Acute Lymphoblastic Leukemia 
  San Diego, CA - 1/19/2012
• The Cure of Chronic Myelogenous Leukemia 
  San Diego, CA - 1/19/2012
• CML:Making a Choice Between Imatinib, Nilotinib and Dasatinib? Update on their Relative Advantages and Toxicities, Innovative Cancer Therapy for Tomorrrow 
  New York City, NY - 1/7/2012
• Lessons from CML: How Applying Targeted Therapy to Newly Diagnosed Disease Transformed Outcomes 
  Chicago, IL - 1/4/2012
• Update on the Satus of Drug Shortages, Causes, and Trends 
  Chicago, IL - 1/3/2012
• Drug Shortages: Why Is This Happening and How Can We Treat Our Patients? 
  Chicago, IL - 1/3/2012
• "Symposium MDS". Developmental Therapeutics in MDS, Leukemia and Lymphoma; East and West are Together 
  MD Anderson Cancer Center and Clinical Hospital Center Zagreb, Dubrovnik, Croatia - 1/17/2011
• "Symposium AML". Developmental Therapeutics in AML, Leukemia and Lymphoma; East and West are Together 
  MD Anderson Cancer Center and Clinical Hospital Center Zagreb, Dubrovnik, Croatia - 1/17/2011
• Imatinib-resistant chronic myeloid leukemia. Definitions and management 
  London, United Kingdom - 1/10/2011
• "Presidential Symposium" and Session: Chronic myeloid leukemia – therapy with TKI," and Speaker "AML – Risk adapted therapy II," East and West Together 
  Dubrovnik, Croatia - 1/15/2007
• Insights into the molecular biology of acute leukemia and the implications for treatment 
  San Diego, CA - 1/19/2005
• Is CML a curable malignancy without transplantation? 
  San Diego, CA - 1/19/2005
• What is new in AML, MDS and CML 
  Cleveland Cancer Center, Cleveland, OH - 1/16/2005
• Update on AML and MDS 
  NYU Medical Center, New York City, NY - 1/25/2004
• Novel approaches in AML and MDS 
  Memorial Sloan Kettering Cancer Center, New York City, NY - 1/25/2004
• CML State of the Art 
  Mt. Sinai Medical Center, New York City, NY - 1/24/2004
• Philadelphia chromosome positive ALL 
  Beirut, Lebanon - 1/19/2004
• Chronic myelogenous leukemia - what’'s new 
  The Winship Cancer Institute of Emory University - 1/17/2004
• Join now to see all

Other

• Health Care in the U.S. Should be a Basic Human Right, not an Entitlement 
  Jones G, Kantarjian H, Baker Institute Blog
  1/1/2015
• What is the 340B Drug Discount Program and why is it so important? 
  Kantarjian H, Chapman R, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2015
• Insurers Play to Win, but the Patients Lose 
  Jain N, Kantarjian H, The Houston Chronicle Outlook Section
  1/1/2015
• Expanding Medicaid under ACA Would Avert State Health Crisis 
  Kantarjian H, Ho V, The Houston Chronicle
  1/1/2015
• High Cost of Cancer Drugs Goes Beyond the Price 
  Kantarjian H, Modern Healthcare
  http://www.modernhealthcare.com/article/20150404/MAGAZINE/304049978
  1/1/2015
• Patients Take Action Against Cancer Drug Prices 
  Kantarjian H, The Houston Chronicle
  1/1/2015
• Does the United States Have the Best Health-Care System in the World? 
  Kantarjian, H, The ASCO Post
  1/1/2014
• The Promise of Cognitive Computing in Cancer Care 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Health care news from Africa: Thumbs Up For Bush, down for pharma 
  Kantarjian, H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Parallels between the Affordable Care Act and the Civil Rights Act of 1964 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Chemotherapy Drug Shortages in the U.S.-The Recurring Nightmare 
  Kantarjian H, Ho, V, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• The Case for Universal Vaccination Against the Human Papillomavirus (HPV) 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Texas and Medicaid 
  Kantarjian H, Ho V, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Deciphering the Hippocratic Oath in the 21st Century 
  Kantarjian H, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2014
• Relevance of the Hippocratic Oath in the 21st Century 
  Kantarjian H, Steensma D, The ASCO Post
  1/1/2014
• HPV vaccine should be Texas requirement 
  Matthews Kirstin RW, Kantarjian Hagop, The Houston Chronicle
  1/1/2014
• America's Health Care System Not as Perfect as We Think 
  Kantarjian, H, The Houston Chronicle
  1/1/2014
• Common Ground on Cutting Costs of Cancer 
  Kantarjian H, Newcomer L, Crenshaw N, The Hill.com
  http://thehill.com/blogs/congress-blog/healthcare/207631-common-ground-on-cutting-costs-of-cancer
  1/1/2014
• Cancer Rx: The $100,000 Myth 
  Light D, Kantarjian H, AARP
  1/1/2014
• An Unhealthy System 
  Kantarjian, H, US News.com
  http://www.usnews.com/opinion/articles/2014/05/30/no-the-us-doesnt-have-the-best-health-care-system-in-the-world
  1/1/2014
• New Trove of Medicare Cost Data an Eye-Opener 
  Kantarjian H, Ho V, The Houston Chronicle
  1/1/2014
• State Policies and ACA Information Gap Hurt the Uninsured 
  Kantarjian, H, The Houston Chronicle
  1/1/2014
• Medical Advances Continue to Help in Cancer Fight 
  Kantarjian H, Mendelsohn J, The Houston Chronicle
  1/1/2014
• U.S. needs universal health care 
  Leonard Zwelling, Hagop Kantarjian, Houston Chronicle (Outlook, Government Section)
  1/1/2013
• Drug Approvals in Acute Myeloid Leukemia: Can We Do Better? 
  Kantarjian H, Estey E, The ASCO Post
  1/1/2013
• Join now to see all